In vitro

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System.   The system will initially be investigated for improving the preclinical estimation of human drug bioavailability compared to standard animal models.  Dr Emily […]

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations […]

A new In Vitro Pharmacology Working Group to accelerate regulatory submissions has been created by the Pistoia Alliance, a global advocate for greater collaboration in life sciences R&D. The group will include liaisons from the US Food and Drug Administration’s Center for Drug Evaluation and Research, as well as representatives from biopharmaceutical companies, contract research […]

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels.  These sequence-defined, recombinant antibodies are suitable for developing highly selective and […]

Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Agilent has released a mitochondrial toxicity infographic to help you discover the benefits of novel in vitro strategies for consumer safety. This infographic is designed to help: Gain a historical perspective on mitochondrial toxicity. Understand the importance of testing in […]

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform also allows for efficacy testing […]

This paid-for advertorial by Manchester BioGel appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Communication of cells with their microenvironment is vital in understanding intracellular processes. Most matrices lack the mechanical and biochemical tuneability necessary to recreate the cancer microenvironment. Here we discuss how PeptiGels are able […]

An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs to treat liver and kidney cells, […]

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing drug toxicity: new approaches and […]

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488 guideline, with these studies playing […]